Key result
Default prasugrel shows no benefit over default ticagrelor for primary events at 1 year.
Why the trial?
Ticagrelor's twice-daily dosing, dyspnoea and bleeding drive frequent discontinuation after acute coronary syndrome. Whether routinely switching from ticagrelor to once-daily prasugrel improves outcomes had not been tested at scale in a randomised setting.
Does a default prasugrel policy reduce ischemic events compared to a default ticagrelor policy in adults undergoing percutaneous coronary intervention for acute coronary syndrome?
Population
17,095 ACS patients after PCI in Sweden (mean age 69.8, 27.8% female)
Comparison
Default prasugrel policy vs default ticagrelor policy
Design
Registry-based open-label stepped-wedge cluster-randomized trial
Follow-up
1 year
Authors
Cardiology · Sahlgrenska University Hospital
What should clinicians watch for when these results land?
SWITCH SWEDEHEART co-author
Great study pioneering to use of cluster randomization in registries to test different treatment strategies in real life. Very useful cost-effective model when implementing novel treatment strategies in the real life setting. The comparison of the strategies "prasugrel first choice" vs "ticagrelor first choice" turned out neutral on efficacy - safety difficult to evaluate in this setting. Good to have two similar alternatives to tailor to different patients and settings.
Experts read SWITCH SWEDEHEART as a well-designed pragmatic trial showing no clear winner between prasugrel and ticagrelor after PCI for ACS, with most commentary focused on the novelty of the policy-level design rather than any practice-changing signal.
The reaction treats this as a null result for the primary ischemic endpoint, with a modest bleeding signal favoring prasugrel that drew some attention. Several voices highlight that this was a comparison of default prescribing policies, not a head-to-head drug trial, and that crossover diluted the contrast. The live question is whether the bleeding difference and the pragmatic design are enough to nudge guidelines toward prasugrel as the preferred default.
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Whether the bleeding reduction with the prasugrel policy is large enough to shift guidelines, given that the primary ischemic endpoint was not significantly different. The limited uptake of prasugrel in the prasugrel-policy group (about 61%) raises the question of what a purer comparison would show. It also remains open whether subgroups such as older patients or those with prior stroke, who are typically excluded from prasugrel, would alter the interpretation.
Davide CapodannoInterventional / Structural Cardiology · University of CataniaEndpoint critiqueAug 30Capodanno stresses that SWITCH-SWEDEHEART is a comparison between policies, not between drugs. He notes that the policy-recommended agent was dispensed to 75.8% in the ticagrelor group but only 60.6% in the prasugrel group, raising questions about what drove the bleeding difference.
Damluji walks through the trial design and context, noting that the choice between prasugrel and ticagrelor has remained unanswered and that SWITCH-SWEDEHEART used a registry-based, stepped-wedge, cluster-randomized approach to test it at scale.
Asher recaps the primary result: death, MI, or stroke at 1 year was 11.1% versus 11.8% with an adjusted OR of 0.90 (95% CI 0.77-1.06), confirming no significant difference.
Neither default policy reduces ischemic events more than the other in ACS after PCI; confirms comparable real-world effectiveness and safety.
| Outcome | Prasugrel | Ticagrelor |
|---|---|---|
| Death, MI, or stroke at 1 year | 11.1% | 11.8% |
| Adjusted OR 0.90 (95% CI 0.77-1.06) - no significant difference between policies | ||
Safety
Major bleeding 4.2% vs 4.4%; adjusted OR 0.80 (95% CI 0.64-0.99).
Design limitations
policy-level cluster comparison (regions switched defaults) rather than individual-patient randomization, open-label with outcomes ascertained from national registries.
Statistical certainty
estimates required adjustment for cluster and calendar time in a stepped-wedge design.
Does a default prasugrel policy reduce ischemic events compared to a default ticagrelor policy in adults undergoing percutaneous coronary intervention for acute coronary syndrome?
Odds Ratio: 0.9 (95% CI 0.77–1.06)
Absolute Event Rate: 11.1% vs 11.8%
In patients undergoing PCI for ACS, a default prasugrel policy did not significantly reduce ischemic events at 1 year compared to a default ticagrelor policy.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Ömerovic et al. (2026) conducted an RCT in Acute coronary syndrome (n=17,095). Prasugrel vs. Ticagrelor was evaluated on Composite of death from any cause, fatal or nonfatal myocardial infarction, or fatal or nonfatal stroke (OR 0.90, 95% CI 0.77 to 1.06). In patients with acute coronary syndrome undergoing PCI, a default prasugrel policy did not lower the risk of ischemic events compared with a default ticagrelor policy (OR 0.90; 95% CI 0.77-1.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
